For most GLP-1 trials, HR is included as a secondary safety endpoint, and the results have been inconsistent
Research on neurotransmitter-system interactions has also been compiled in recent reviews, broadening the picture beyond the classical angiogenic and gastric framings (PMID 38675421)
10.3389/fnins.2020.00131 317 MenozziE.SchapiraA
From GLP-1s to longevity and new views on self-care for healthcare, the people are taking their health in-hand, at-home, and via-tech to complement and sometimes replace the legacy health system touchpoints which are the traditional categories for care: hospitals, doctors, rehab centers, diagnostics and labs, and health care financing and plans some opting out of plans and going full-risk (cash, out-of-pocket) truly self-insuring against future medical risks
J Exp Med (2019) 216(1):6070